Aytu BioPharma Files 8-K with Corporate Updates
Ticker: AYTU · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1385818
| Field | Detail |
|---|---|
| Company | Aytu Biopharma, Inc (AYTU) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: AYTU
TL;DR
AYTU filed an 8-K on Aug 6th, updating corporate info & former names.
AI Summary
Aytu BioPharma, Inc. filed an 8-K on August 6, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 7900 East Union Avenue, Suite 920, Denver, CO 80237. The company was formerly known as Aytu Bioscience, Inc. and Rosewind Corp.
Why It Matters
This filing provides essential corporate information and updates for investors and stakeholders regarding Aytu BioPharma's official reporting and structure.
Risk Assessment
Risk Level: low — This filing is primarily administrative and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- AYTU BIOPHARMA, INC (company) — Registrant
- August 6, 2024 (date) — Date of Report
- 7900 East Union Avenue, Suite 920, Denver, CO 80237 (location) — Principal executive offices
- Aytu Bioscience, Inc. (company) — Former Company Name
- Rosewind Corp (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for Aytu BioPharma, Inc.?
The primary purpose of this 8-K filing is to report on a Regulation FD Disclosure and to provide Financial Statements and Exhibits, along with updating corporate information.
When was the report filed and what is the earliest event date reported?
The report was filed on August 6, 2024, and the date of the earliest event reported is also August 6, 2024.
Where are Aytu BioPharma, Inc.'s principal executive offices located?
The principal executive offices of Aytu BioPharma, Inc. are located at 7900 East Union Avenue, Suite 920, Denver, CO 80237.
What were some of Aytu BioPharma, Inc.'s former company names?
Aytu BioPharma, Inc. was formerly known as Aytu Bioscience, Inc. and Rosewind Corp.
Under which sections of the Securities Exchange Act of 1934 is this Current Report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-08-06 08:00:12
Key Financial Figures
- $0.0001 — ch Registered Common Stock , par value $0.0001 per share AYTU The Nasdaq Capital M
Filing Documents
- aytu20240730_8k.htm (8-K) — 25KB
- ex_705544.htm (EX-99.1) — 11KB
- logo01.jpg (GRAPHIC) — 4KB
- logo.jpg (GRAPHIC) — 4KB
- 0001437749-24-024725.txt ( ) — 184KB
- aytu-20240806.xsd (EX-101.SCH) — 3KB
- aytu-20240806_def.xml (EX-101.DEF) — 12KB
- aytu-20240806_lab.xml (EX-101.LAB) — 15KB
- aytu-20240806_pre.xml (EX-101.PRE) — 12KB
- aytu20240730_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 6, 2024, Aytu issued a press release titled "Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release dated August 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AYTU BIOPHARMA, INC. Date: August 6, 2024 By: /s/ Mark K. Oki Mark K. Oki Chief Financial Officer